Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults
- 1 February 1986
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 29 (2) , 339-341
- https://doi.org/10.1128/aac.29.2.339
Abstract
In a randomized, double-blind trial involving patients with uncomplicated influenza A H3N2 subtype virus infection, rimantadine treatment (200 mg/day for 5 days) was associated with significant reductions in nasal secretion viral titers (days 2 through 4), maximal temperature (days 2 and 3), time until defervescence (mean, 37 h shorter), and systemic symptoms compared with placebo treatment.This publication has 7 references indexed in Scilit:
- Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adultsAntimicrobial Agents and Chemotherapy, 1985
- Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokineticsAntimicrobial Agents and Chemotherapy, 1983
- A Controlled Trial of Amantadine and Rimantadine in the Prophylaxis of Influenza a InfectionNew England Journal of Medicine, 1982
- Successful treatment of naturally occurring influenza A/USSR/77 H1N1Published by American Medical Association (AMA) ,1981
- Plaque inhibition assay for drug susceptibility testing of influenza virusesAntimicrobial Agents and Chemotherapy, 1980
- Therapeutic Efficacy of Amantadine HCl and Rimantadine HCl in Naturally Occurring Influenza A2 Respiratory Illness in ManNew England Journal of Medicine, 1969
- Treatment of Influenza. The Therapeutic Efficacy of Rimantadine HCl in a Naturally Occurring Influenza A2 OutbreakThe Lancet Healthy Longevity, 1969